Salidroside attenuates calcium oxalate-induced renal injury via suppression of PANoptosis

  • Urolithiasis. 2026 Jan 2;54(1):25. doi: 10.1007/s00240-025-01927-6.
Guoxiang Li  #  1  2  3 ,  Zhenyu Song  #  1  2  3 ,  Junfeng Yao  #  1  2  3 ,  Yang Chen  4  5  6 ,  Yuexian Xu  7 ,  Zongyao Hao  8  9  10
Affiliations
  • 1. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • 2. Institute of Urology, Anhui Medical University, Hefei, China.
  • 3. Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China.
  • 4. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. [email protected].
  • 5. Institute of Urology, Anhui Medical University, Hefei, China. [email protected].
  • 6. Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China. [email protected].
  • 7. Department of Emergency Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. [email protected].
  • 8. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. [email protected].
  • 9. Institute of Urology, Anhui Medical University, Hefei, China. [email protected].
  • 10. Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China. [email protected].
  • # Contributed equally.
PMID: 41483174 DOI: 10.1007/s00240-025-01927-6
Keywords
Kidney stones; Network pharmacology; PANoptosis; Salidroside.
Products